The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2009 Release

December 24, 2009 Submission of the New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan
December 18, 2009 Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
December 17, 2009 Eisai Opens New Manufacturing and Process Research Base in India
December 1, 2009 Eisai Launches New Oral Jelly Formulation of Aricept®
November 25, 2009 FDA Accepts for Review Eisai's NDA for Aricept® 23mg Extended Release Tablets in the United States
November 17, 2009 Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
October 30, 2009 GLOBAL PHASE III STUDY RESULTS SHOW ERIBULIN MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL
October 30, 2009 Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai’s Anticancer Compounds
October 28, 2009 Abbott Submits Marketing Authorization Application of Humira® (adalimumab), a Fully Human Monoclonal anti-TNF-alpha Antibody, for the Treatment of Ankylosing Spondylitis in Japan
October 26, 2009 Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan
October 19, 2009 Eisai Launches “Crystal Veil”- an Allergen Screen Topical Gel
October 16, 2009 Eisai Opens Regional Office in Bahrain
October 1, 2009 Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
September 30, 2009 Abbott and Eisai Submit Application for Approval of Humira® (Adalimumab), a Fully Human Monoclonal Anti-TNF-alpha Antibody, for the Treatment of Crohn's Disease in Japan
September 29, 2009 Eisai and DND Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease
September 29, 2009 Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET® for Non-erosive GERD in Japan
September 29, 2009 KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
September 25, 2009 Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept®
July 31, 2009 Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
July 28, 2009 Eisai Signs License Agreement with Biocompatibles International for Drug-Eluting Bead Products for Embolisation
July 27, 2009 Eisai Files Submission to Health Authorities in Switzerland for E7389, Novel Anti-cancer Agent, for the Treatment of Metastatic and Locally Advanced Breast Cancer
July 22, 2009 Eisai Receives Approval for a New Oral Jelly Formulation of Aricept® for the Treatment of Alzheimer’s Disease in Japan
July 14, 2009 Eisai Signs License Agreement in Japan for MENILET®, an Oral Osmotic Diuretic and Meniere’s Disease-Improving Agent
July 8, 2009 FDA Accepts sNDA for Alternative Dosing of Dacogen® to Treat Patients with Myelodysplastic Syndromes (MDS)
July 6, 2009 Eisai to Initiate Clinical Trial of Dacogen® in Pediatric Patients with Acute Myelogenous Leukemia in the US
July 6, 2009 Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
July 2, 2009 Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value
June 26, 2009 Eisai Establishes “European Knowledge Centre” as its European Strategic Base
June 19, 2009 Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 17, 2009 Eisai Sets Up a Subsidiary in Austria
June 1, 2009 Sanko Junyaku Launches Diagnostic Reagent Kit For Automated Clinical Chemistry Analyser To Determine KL-6, Detecting Marker of Interstitial Pneumonia
May 18, 2009 SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore
May 14, 2009 Notice on New Stock Issuance in the Form of Stock Options
May 9, 2009 Regarding the Statement in Pfizer's 10-Q Report Dated May 8th, 2009
April 28, 2009 Novel Anti-epileptic ZEBINIX® Approved in the European Union
April 6, 2009 License Agreement for GLIADEL® WAFER in Japan Signed
April 2, 2009 Kissei and Eisai Sign License Agreement for Urief®, A Treatment for Dysuria Associated with Benign Prostatic Hyperplasia for ASEAN Countries, India, and Sri Lanka
March 27, 2009 Notice of Revised Non-consolidated Business Forecast for Fiscal Year Ending March 31, 2009
March 24, 2009 Toyama Chemical and Eisai Decide to Conduct Additional Study for Anti-Rheumatic Drug T-614
March 13, 2009 Approval of Clevudine for the Treatment of Chronic Hepatitis B in the Philippines
February 26, 2009 Eisai and Teikoku Seiyaku Sign Agreements on Transdermal Patch Formulation of Donepezil Hydrochloride
February 26, 2009 Eisai Announces Termination of Joint Development Agreement with Nitto Denko on a Transdermal Patch Formulation of Aricept®
February 23, 2009 Eisai Introduces Nabolin® Felbinac 70 for severe shoulder pain and low back pain
February 20, 2009 Eisai Signs License Agreement in Europe for an Anti-epileptic Drug
February 10, 2009 Ajinomoto and Eisai Sign Agreement for Distribution of Branched-chain Amino Acid Formula LIVACT® Granules in Asia
February 9, 2009 Eisai Introduces Travelmin® Churop Grape Flavor The First OTC Motion Sickness Remedy in Drop Type

Back to Top